程序性死亡配体1(PD-L1)又称CD274或B7同源物1(B7-H1)，是一种跨膜蛋白，通过与程序性死亡-1(PD-1)受体的结合，抑制免疫系统，使肿瘤细胞抵抗CD8+T细胞介导的杀伤。PD-L1的过度表达可能使癌细胞逃避宿主免疫系统的作用。在肾细胞癌中，PD-L1的表达上调与肿瘤侵袭性和死亡风险增加有关，而在卵巢癌中，PD-L1的高表达会导致明显的不良预后。PD-L1还与系统性红斑狼疮和皮肤黑色素瘤有关。当与CD8+肿瘤浸润淋巴细胞密度联合考虑时，PD-L1的表达水平可能是预测多种癌症类型的有用指标，包括III期非小细胞肺癌、激素受体阴性乳腺癌和前哨淋巴结黑色素瘤。

Programmed Death-Ligand 1 (PD-L1), also known as CD274 or B7 Homolog 1 (B7-H1), is a transmembrane protein involved in suppressing the immune system and rendering tumor cells resistant to CD8+ T cell-mediated lysis through binding of the Programmed Death-1 (PD-1) receptor. Overexpression of PD-L1 may allow cancer cells to evade the actions of the host immune system. In renal cell carcinoma, upregulation of PD-L1 has been linked to increased tumor aggressiveness and risk of death, and, in ovarian cancer, higher expression of this protein has lead to significantly poorer prognosis. PD-L1 has also been linked to systemic lupus erythematosus and cutaneous melanoma. When considered in adjunct with CD8+ tumor-infiltrating lymphocyte density, expression levels of PD-L1 may be a useful predictor of multiple cancer types, including stage III non-small cell lung cancer, hormone receptor negative breast cancer, and sentinel lymph node melanoma.

 

Clone IHC411

Source Rabbit Monoclonal

Positive Control Tonsil, Lung Adenocarcinoma

Dilution Range 1:50-1:200

 

Ostrand-Rosenberg S, et al. J Immunol. 2014; 193:3835-41.

Tokito T, et al. Eur J Cancer. 2016; 55:7-14.

Park IH, et al. Clin Breast Cancer. 2016; 16:51-8.

Kakavand H, et al. Mod Pathol. 2015; 28: 1535-44.

Xia B, et al. Immunotherapy. 2016; 8:279-98.

Patel SP, et al. Mol Cancer Ther. 2015; 14:847-56.

Singh BP, et al. Cancers (Basel). 2016; 8.

Chemnitz JM, et al. J Immunol. 2004; 173:945–54.

Thompson RH, et al. Proc Natl Acad Sci USA. 2004; 101:17174–9.

Hamanishi J, et al. Proc Natl Acad Sci USA. 2007; 104:3360–5.

Mozaffarian N, et al. Rheumatology, 2008; 47:1335–41.